Chinese Hamster Ovary (i.e., Cho) Patents (Class 435/358)
-
Publication number: 20130344604Abstract: The present invention relates to an expression cassette useful for the expression of a polynucleotide sequence encoding a polypeptide.Type: ApplicationFiled: December 5, 2012Publication date: December 26, 2013Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Christel Aebischer-Gumy, Martin Bertschinger, Daniel Luescher, Pierre Moretti
-
Publication number: 20130344535Abstract: The invention relates to a method for removing a viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. The method comprises subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum about 75 nm. Further, the invention relates to the use of a virus filter in filtration of at least about 24 hours, wherein the virus filter has an effective pore size of maximum about 75 nm for the removal of viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. In some embodiments the filtration according to the invention operates at a volumetric capacity of at least about 2000 L/m2.Type: ApplicationFiled: June 19, 2013Publication date: December 26, 2013Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Wolfgang Mundt, Artur MITTERER, Manfred REITER, Meinhard HASSLACHER, Leopold GRILLBERGER, Thomas KRElL
-
Patent number: 8614306Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.Type: GrantFiled: August 22, 2012Date of Patent: December 24, 2013Assignee: Genentech, Inc.Inventors: Arthur Huang, Robert Kelley, Henry Lowman, Menno Van Lookeren Campagne, Charles Winter
-
Publication number: 20130337503Abstract: The present invention provides a mutant 27 kDa NIa proteinase having reduced self-cleavage activity relative to the self-cleavage activity of its wild-type proteinase. The mutant has the same substrate cleavage activity as the wild-type proteinase but is more stable than the wild-type proteinase. The present invention also provides a method of obtaining large quantities of active 27 kDa NIa proteinase for use as a tool for purification of other proteins.Type: ApplicationFiled: May 21, 2013Publication date: December 19, 2013Applicant: YALE UNIVERSITYInventors: Jennifer A. DOUDNA, Louise J. Lucast, Robert T. Batey
-
Publication number: 20130337506Abstract: The present invention is related to a cell culture medium for the expression of a protein, which medium comprises a PAM inhibitor, or a physiological equivalent thereof, and to a cell culture process for the expression of a protein, in which process a PAM inhibitor, or a physiological equivalent thereof, is used (FIG. 1).Type: ApplicationFiled: November 9, 2011Publication date: December 19, 2013Applicant: SANDOZ GMBHInventors: Corinna Sonderegger, Julia Schmutzhard, Christine Heel, Thomas Stangler
-
Publication number: 20130336924Abstract: The present invention provides fusion polypeptides comprising polypeptide ligands that are modified by circular permutation and fused to at least one polypeptide fusion partner wherein such fusion polypeptides have new, improved or enhanced biological functions or activities. Such improvements include, but are not limited to, increased binding affinity, increased activity, increased agonist activity (super agonist), antagonist activity, increased accessibility, increased flexibility of the active site, increased stability, broader and/or changed substrate specificity, and combinations thereof.Type: ApplicationFiled: June 6, 2013Publication date: December 19, 2013Inventors: JUAN ALVAREZ, JEAN CHAMOUN
-
Patent number: 8609342Abstract: The invention provides a reporter gene assay method by which the sex hormone-like activity inherent in a test substance can be accurately assayed excluding the effects caused by a decrease in cell activity (protein expressing capacity). The assay method is a reporter gene assay method using luciferase-expressing cells which comprises further transferring a GFP gene into the luciferase-expressing cells, measuring the luciferase expression level and GFP expression level, and making a judgment about the thus-measured luciferase expression level using the decrease in GFP expression level as an indication of the decrease in cell activity.Type: GrantFiled: December 13, 2002Date of Patent: December 17, 2013Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Mitsuru Iida, Hideo Oguri
-
Patent number: 8609372Abstract: A glycosyl transferase from Chinese hamster and related methods are described.Type: GrantFiled: November 10, 2010Date of Patent: December 17, 2013Assignee: Momenta Pharmaceuticals, Inc.Inventor: James W. Meador, III
-
Patent number: 8603778Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.Type: GrantFiled: July 12, 2012Date of Patent: December 10, 2013Assignee: Janssen Biotech, Inc.Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
-
Publication number: 20130324593Abstract: The present invention relates to a hybrid promoter, in which a whole or a part of a CMV enhancer, a whole or a part of a ?-actin promoter, a whole or a part of a CMV promoter, and a whole or a part of a ?-actin intron are operably linked to each other, a recombinant vector comprising the same, a transformant transformed with the recombinant vector, a pharmaceutical composition comprising the recombinant vector or the transformant, and a method for preparing a target protein using the recombinant vector or the transformant. The hybrid promoter of the present invention is able to induce high expression of a target protein in a eukaryotic cell. Therefore, the hybrid promoter of the present invention can be effectively used for the development of an antibody or the production of a DNA vaccine.Type: ApplicationFiled: November 29, 2011Publication date: December 5, 2013Applicant: LG Life Sciences LtdInventors: Yeon Chul Kim, Saem Jung, Jun Jung
-
Publication number: 20130323187Abstract: The present invention describes material and methods related to synthetic peptides which block the secretion of neurotransmitters and induce muscle relaxation, and use of said peptides as inhibitors of neurotransmitter secretion and muscle contraction, and as inducers of muscle relaxation.Type: ApplicationFiled: November 26, 2012Publication date: December 5, 2013Applicant: PARTNERSHIP & CORP. TECHNOLOGY TRANSFERInventors: Nicolas Fasel, Amal Kuendig
-
Patent number: 8597910Abstract: Von Willebrand's Factor (VWF) is produced using an expression vector that includes: 1) a DNA sequence encoding a functional VWF protein; and 2) regulatory DNA capable of effecting expression of that DNA sequence in a host cell transformed with the vector. Restriction fragment length polymorphisms (RFLP's) associated with the VWF gene are identified and used in a probe for determining the source of a VWF gene in a DNA sample. The gene for VWF is localized to the short arm of human chromosome 12 (12p).Type: GrantFiled: July 23, 1990Date of Patent: December 3, 2013Assignee: Children's Medical Center CorporationInventors: David Ginsburg, Stuart H. Orkin, Randal J. Kaufman
-
Publication number: 20130316946Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise modified C-peptide derivatives which exhibit superior pharmacokinetic and biological activity in vivo.Type: ApplicationFiled: May 24, 2013Publication date: November 28, 2013Applicant: Cebix, Inc.Inventor: Sheri BARRACK
-
Publication number: 20130316959Abstract: C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.Type: ApplicationFiled: July 10, 2013Publication date: November 28, 2013Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Carol A. Feghali-Bostwick, Yukie Yamaguchi
-
Publication number: 20130316404Abstract: The present invention relates to a polypeptide having interleukin-10 function, comprising two interleukin-10 monomer subunits covalently linked by a linker. The present invention further relates to a nucleic acid molecule encoding the polypeptide of the invention, a vector comprising said nucleic acid molecule, a non-human host transformed with the nucleic acid molecule or the vector of the invention as well as a method for the production of a recombinant polypeptide of the invention. The present invention further relates to a pharmaceutical composition as well as to the polypeptide, the nucleic acid molecule, the vector or the host or host cell of the invention for use in treating and/or preventing inflammatory diseases.Type: ApplicationFiled: November 25, 2011Publication date: November 28, 2013Applicants: THE UNIVERSITY OF MANCHESTER, TECHNISCHE UNIVERSITÄT DRESDENInventors: Axel Roers, Sebastian Lanvermann, Werner Müller
-
Publication number: 20130316962Abstract: The present invention relates to novel muteins derived from human lipocalin 2 (hNGAL) and related proteins that bind a given non-natural ligand with detectable affinity. The invention also related to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. Furthermore, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: ApplicationFiled: April 9, 2013Publication date: November 28, 2013Applicant: TECHNISCHE UNIVERSITÄT MÜNCHENInventors: Arne Skerra, Andreas Eichinger, Hyun-Jin Kim
-
Publication number: 20130316952Abstract: Non-natural albumin binding domains, polynucleotides encoding thereof and methods of making and using these domains and polynucleotides are useful in controlling the half-life of therapeutic molecules for patients.Type: ApplicationFiled: May 23, 2013Publication date: November 28, 2013Applicant: Janssen Biotech, Inc.Inventor: Janssen Biotech, Inc.
-
Publication number: 20130316004Abstract: Methods for increasing the stability of, or protecting, labile components such as ethanolamine, growth factors, vitamins, etc., in compositions such as a cell culture medium. Stability of the labile compound is increased either, by derivatization of the labile compound with chemicals, or by sequestering the labile compound. Sequestering can be done either by encapsulation within a microcapsule, or by the use of sequestering agents. Encapsulation includes the encapsulation of dendrimers complexes of susceptible compounds within the microcapsule, thereby providing the controlled release of the susceptible compound that was protected. These methods may improve and extend storage conditions of compositions comprising the labile compounds, improve shipping and handling of compositions comprising the labile compounds, such as dry media formulations, at room temperature rather than at lower temperatures thereby decreasing shipping costs.Type: ApplicationFiled: February 7, 2012Publication date: November 28, 2013Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Richard Fike, Bruce Branchaud, Shawn Barrett
-
Publication number: 20130310324Abstract: The present invention relates to Huwentoxin-IV variants, polynucleotides encoding them, and methods of making and using the foregoing.Type: ApplicationFiled: March 15, 2013Publication date: November 21, 2013Applicant: JANSSEN BIOTECH, INC.Inventors: Mack Flinspach, Michael Hunter, Yi Liu, Robert Neff, Alan Wickenden, Alan Gibbs
-
Publication number: 20130309752Abstract: The present disclosure generally relates to polypeptides having colanic acid-degrading activity and methods of using the same. Polynucleotides encoding such polypeptides are also described. The polypeptides may be used, for example, in processes for degrading colanic acid, processes for the removal of endotoxins from biological samples, and processes for purifying plasmid DNA.Type: ApplicationFiled: July 30, 2013Publication date: November 21, 2013Applicant: GRADALIS, INC,Inventor: Nancy Smyth Templeton
-
Publication number: 20130309682Abstract: Provided herein is a synthetic or isolated polynucleotide encoding a mammalian 18S rRNA that is resistant to pactamycin. The pactamycin-resistance is conferred by one or more single residue substitutions in the 18S rRNA sequence; a fragment thereof harboring said substitutions; a complementary sequence thereto; or a substantially identical sequence of the foregoing. Related systems, methods and kits are also described.Type: ApplicationFiled: May 21, 2013Publication date: November 21, 2013Inventors: Vincent P. Mauro, Luke Burman, Gerald M. Edelman
-
Publication number: 20130309747Abstract: The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding a) a secretion peptidic signal, b) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT, EC 2.1.1.63), a mutant or a catalytic domain thereof, and c) a recombinant protein. Said MGMT enzyme is preferably the so-called SNAP protein.Type: ApplicationFiled: December 9, 2011Publication date: November 21, 2013Inventors: Philippe Despres, Sylvie Paulous, Elodie Crublet
-
Patent number: 8586356Abstract: The present invention provides methods of evaluating CHO cells.Type: GrantFiled: January 22, 2009Date of Patent: November 19, 2013Assignee: Momenta Pharmaceuticals, Inc.Inventors: Carlos Bosques, Jennifer Murphy, Hetal Sarvaiya, Nathaniel Washburn, Cuihua Liu, Xiao-Jin Xu
-
Publication number: 20130302880Abstract: The invention provides a mutant hydrolase protein with enhanced kinetics and functional expression, as well as polynucleotides encoding the mutant proteins and methods of using the polynucleotides and mutant proteins.Type: ApplicationFiled: April 16, 2013Publication date: November 14, 2013Applicant: PROMEGA CORPORATIONInventors: Aldis Darzins, Lance P. Encell, Rachel Friedman Ohana, Paul Otto, Gediminas Vidugiris, Keith V. Wood, Monika G. Wood, Kris Zimmerman, Michael R. Slater, Kate Qin Zhao
-
Publication number: 20130302886Abstract: The invention provides isolated Pre-Ligand Assembly Domain (PLAD) polypeptides which inhibit multimerization of a receptor complex comprising an IL-17R family member. Related PLAD-binding polypeptides, chimeric proteins, conjugates, nucleic acids, vectors, host cells, and methods are provided herein.Type: ApplicationFiled: May 8, 2013Publication date: November 14, 2013Applicants: RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK, AMGEN INC.Inventors: Sarah L. GAFFEN, Fang Shen, Walter Hanel, Jill Kramer, James P. Malone, Michael Wittekind, Raymond Paxton
-
Publication number: 20130302859Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.Type: ApplicationFiled: May 9, 2013Publication date: November 14, 2013Applicant: CODEXIS,INC.Inventors: CHEN Haibin, Steven J. Collier, Jovana NAZOR, Joly SUKUMARAN, Derek SMITH, Jeffrey C. MOORE, Gregory HUGHES, Jacob JANEY, Gjalt HUISMAN, Scott NOVICK, Nicholas AGARD, Oscar ALVIZO, Gregory COPE, Wan Lin YEO, Stephanie NG
-
Publication number: 20130295072Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.Type: ApplicationFiled: July 1, 2013Publication date: November 7, 2013Inventors: Udi Eyal FIMA, Gili Hart
-
Publication number: 20130298263Abstract: The present invention provides a nucleic acid construct for expressing an oxidative stress indicator comprising: a nucleic acid sequence encoding an Nrf2 protein-derived partial protein that comprises at least an Neh2 domain sequence and substantially lacks or is functionally deficient in an Neh1 domain sequence or an Neh1-Neh3 domain sequence; a stress-inducible promoter sequence positioned upstream of the nucleic acid sequence encoding an Nrf2 protein-derived partial protein; and a nucleic acid sequence encoding a protein capable of generating a detectable signal, the nucleic acid sequence being positioned downstream of the nucleic acid sequence encoding an Nrf2 protein-derived partial protein. The present invention also provides a method for measuring oxidative stress and a method for screening for an anti-oxidative stress agent, using the nucleic acid construct.Type: ApplicationFiled: January 20, 2012Publication date: November 7, 2013Inventors: Takao Iwawaki, Daisuke Oikawa
-
Publication number: 20130296534Abstract: Disclosed is a fusion protein comprising blood coagulation factor IX (FIX) and transferrin. The fusion protein exhibits improved specific FIX activity, as compared to native FIX, and can be useful in the treatment of FIX deficiency-associated diseases.Type: ApplicationFiled: October 19, 2011Publication date: November 7, 2013Applicant: SK CHEMICALS CO., LTD.Inventors: Min Sun Lee, Hun-Taek Kim, Bong-yong Lee, Mahn Hoon Park, Yun Jung Lim
-
Publication number: 20130295667Abstract: The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells.Type: ApplicationFiled: March 20, 2013Publication date: November 7, 2013Inventors: Stephen GORFIEN, Richard Fike, Glenn Godwin, Joyce Dzimian, David Epstein, Dale Gruber, Paul Price
-
Publication number: 20130295596Abstract: The present invention relates to a process for the prediction of cell culture performance data of sample cells, a process for the isolation of said cells and a device for the prediction of cell culture performance data of sample cells.Type: ApplicationFiled: October 27, 2011Publication date: November 7, 2013Applicant: LONZA BIOLOGICS PLCInventors: Dietmar Lang, Elaine B. Martin, Gary A. Montague, Christopher J. O'Malley, Tracy S. Root, Carol M. Trim, Jane F. Povey, Christopher M. Smales, Andrew J. Racher
-
Publication number: 20130295593Abstract: Vitamin D binding proteins (DBP), in particular truncated DBP and mutated, truncated DBP, as well as fusion proteins thereof, nucleic acid molecules encoding same, vectors, host cells, and methods, kits and solid supports for determining the total amount of 25-hydroxy vitamin D2 and 25-hydroxy vitamin D3 in a test sample.Type: ApplicationFiled: December 23, 2012Publication date: November 7, 2013Inventors: Christian Beckert, Susan E. Brophy, Jonathan Grote, Dagang Huang, Jan Schultess, Bailin Tu
-
Publication number: 20130291234Abstract: The present invention relates to a gene encoding Synechocystis putative DNA binding stress protein (SyDBSP protein) derived from cyanobacteria Synechocystis PCC6906; a method for enhancing the salt tolerance of a plant comprising transforming a plant cell with a recombinant vector comprising the SyDBSP gene and overexpressing the SyDBSP gene; a plant having enhanced salt tolerance produced by the aforementioned method, and seed of the plant.Type: ApplicationFiled: October 13, 2011Publication date: October 31, 2013Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Jang Ryol Liu, Suk Weon Kim, Jong Hyun Kim, Sung Ran Min, Won Joong Jeong, Myung Suk Ahn, Young Min Park, Myung Jin Oh, Ji Hyun Park
-
Publication number: 20130288365Abstract: A variety of applications, systems, methods and constructs are implemented for use in connection with screening of ion-channel modulators. Consistent with one such system, drug candidates are screened to identify their effects on cell membrane ion channels and pumps. The system includes screening cells having light responsive membrane ion switches, voltage-gated ion switches and fluorescence producing voltage sensors. A chemical delivery device introduces the drug candidates to be screened. An optical delivery device activates the light responsive ion switches. An optical sensor monitors fluorescence produced by the voltage sensors. A processor processes data received from the optical sensor. A memory stores the data received from the optical sensor.Type: ApplicationFiled: March 26, 2013Publication date: October 31, 2013Inventors: Karl Deisseroth, Feng Zhang, Viviana Gradinaru, M. Bret Schneider
-
Publication number: 20130281356Abstract: The present invention is further directed to methods and compositions for modulating the activity of the Toso protein. The invention further encompasses treatment of disorders associated with inflammation, autoimmune disorders, and cancer using compositions that include a soluble Toso protein.Type: ApplicationFiled: March 14, 2013Publication date: October 24, 2013Inventors: Michael W. Tusche, Tak W. Mak, Pamela S. Ohashi, Philipp Lang, Karl Lang, Dirk Brenner, Gloria Lin
-
Publication number: 20130281671Abstract: The present invention provides methods of reducing nonprocessed Factor VIII or a chimeric polypeptide comprising Factor VIII comprising co-transfecting in a host cell a polynucleotide encoding Factor VIII with a polynucleotide encoding a protein convertase, where the endogenous processing enzymes of the host cell are insufficient to convert all of the Factor VIII to its processed isoform; expressing a proprotein convertase from a second polynucleotide in the host cell; and reducing the nonprocessed Factor VIII by processing with said proprotein convertase.Type: ApplicationFiled: July 11, 2011Publication date: October 24, 2013Applicant: Biogen Idec Hemophilia Inc.Inventors: Robert T. Peters, Susan C. Low
-
Publication number: 20130280274Abstract: The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the distribution or amount of lysine variants expressed by host cells, as well as to compositions and processes for controlling the amount of lysine variants present in purified preparations.Type: ApplicationFiled: March 14, 2013Publication date: October 24, 2013Applicant: ABBVIE INC.Inventors: Kartik Subramanian, Mayda Perez, Xiaobei Zeng, Chee Furng Wong
-
Publication number: 20130281379Abstract: The invention relates to mutant channelrhodopsins having improved properties, nucleic acid constructs encoding same, expression vectors carrying the nucleic acid construct, cells comprising said nucleic acid construct or expression vector, and their respective uses.Type: ApplicationFiled: September 8, 2011Publication date: October 24, 2013Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaftern e.V.Inventors: Ernst Bamberg, Christian Bamann, Sonja Kleinlogel, Phillip Wood, Robert E. Dempski
-
Patent number: 8563303Abstract: The present invention relates to the field of cell culture technology and relates to methods of replicating/cloning cells, preferably cell lines which are important for the production of biopharmaceuticals. The invention also relates to methods of preparing proteins using cells that have been obtained and replicated by single cell deposition and compositions which make it possible to replicate individual cells. By using IGF particularly in conjunction with HSA in the culture medium after recloning, the recloning efficiency and hence the quantity of clones obtained can be increased significantly.Type: GrantFiled: March 16, 2009Date of Patent: October 22, 2013Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Jüergen Fieder, Lore Florin, Hitto Kaufmann, Thomas Krieg, Melanie Briegel
-
Publication number: 20130273021Abstract: The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.Type: ApplicationFiled: March 11, 2011Publication date: October 17, 2013Applicant: SYNAGEVA BIOPHARMA CORP.Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
-
Publication number: 20130273650Abstract: The present invention discloses a series of eukaryotic expression vectors utilizing the reduction of transcription read-through events to create stable and high-yield cell lines for recombinant protein expression. The vectors comprise more than one polyadenylation signal or one or more polyadenylation signals plus other DNA fragment which is known to enhance transcription termination to control the expression level of selection marker, with the configuration to transcribe the minimal level of full-length bicistronic mRNA to express the selection marker, which can be used to create stable cell lines at high expression levels, without the need for drug selection or drug mediated gene amplification.Type: ApplicationFiled: July 26, 2011Publication date: October 17, 2013Applicant: ADV BIOLOGICS ,INC.Inventor: Xiaoyun Wu
-
Publication number: 20130273604Abstract: This invention relates to a method for producing a protein of interest, comprising introducing an expression vector which comprises a gene fragment comprising a DNA encoding the protein of interest and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment, into a suspension mammalian cell; integrating the gene fragment inserted between the pair of transposon sequences into a chromosome of the mammalian cell; obtaining a suspension mammalian cell producing the protein of interest; and suspension-culturing the suspension mammalian cell, and a suspension mammalian cell which expresses the protein of interest by the method.Type: ApplicationFiled: December 14, 2011Publication date: October 17, 2013Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Megumi Kurokawa, Yoko Hayashi, Masayoshi Tsukahara
-
Publication number: 20130273634Abstract: A method for the mass production of human coagulation factor VII. The method includes a) providing an expression vector carrying i) a dihydrofolate reductase promoter devoid of one or more CCGCC repeat sequences from the GC-rich region thereof and a dihydrofolate reductase (DHFR) gene operably linked thereto and ii) a cytomegalovirus (CMV) promoter and a human coagulation factor VII gene operably linked thereto; b) obtaining a transformed a host cell line containing the expression vector; and c) culturing the transfected host cell in the presence of a dihydrofolate reductase inhibitor to select cells which express human coagulation factor VII with high efficiency; and d) adding sodium butyrate to the selected host cells.Type: ApplicationFiled: October 26, 2011Publication date: October 17, 2013Applicant: HANMI SCIENCE CO., LTD.Inventors: Chang Hwan Kim, Sung Kap Hong, Byung Sun Lee, Sung Hwan Hong, Se Chang Kwon
-
Publication number: 20130273044Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.Type: ApplicationFiled: November 2, 2012Publication date: October 17, 2013Inventors: Austin GURNEY, John Lewicki, Sanjeev Satyal, Timothy Hoey
-
Patent number: 8557546Abstract: This invention relates to a recombinant human G-CSF (rhG-CSF) dimer and its use in the treatment of neurological disorder. In particular, upon ischemic neural injury in animal, this invention can be used to protect neurons with the use of rhG-CSF dimer such that function of injured nerves can be restored. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased.Type: GrantFiled: May 23, 2011Date of Patent: October 15, 2013Assignee: Generon (Shanghai) CorporationInventors: Xiaoqiang Yan, Zhihua Huang, Hongzhou Yang, Bill N. C. Sun, Yuliang Huang
-
Publication number: 20130267684Abstract: Provided are a method for preparing a highly versatile aqueous solution having remarkably improved membrane filterability, which can be stably membrane-filtered in a short time, an aqueous solution prepared by the preparation method, a method for culturing cells using the aqueous solution which is prepared by the preparation method, a method for producing a physiologically active substance using the culturing method, a physiologically active substance produced by the method for producing a physiologically active substance, a method for performing membrane filtration of the aqueous solution which is prepared by the preparation method of the aqueous solution, a method for improving membrane filterability of the aqueous solution, and a method for producing the physiologically active substance by preparing the aqueous solution, performing membrane filtration of the aqueous solution, and then culturing cells using the resulting aqueous solution.Type: ApplicationFiled: December 27, 2011Publication date: October 10, 2013Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Yoshinobu Konno, Kairo Wakamatsu, Yasufumi Imamoto, Jun Ishibashi, Ken Takahashi, Hisaya Tanaka
-
Patent number: 8551776Abstract: The present invention provides isolated polypeptides having an amino acid sequence having at least 70% identity to SEQ ID NO:20, wherein the polypeptide has ER-?36 activity. The invention further provides methods for identifying agents that bind to such polypeptides, methods for detecting such polypeptides, and methods for altering the activity of such polypeptides. Also provided are antibodies that specifically bind to an amino acid sequence depicted at SEQ ID NO:1, or an immunogenic fragment thereof, and methods for making and using such antibodies.Type: GrantFiled: August 7, 2012Date of Patent: October 8, 2013Assignee: Creighton UniversityInventor: Zhao Yi Wang
-
Publication number: 20130260456Abstract: Recombinant proteins capable of inducing platelet aggregation and uses thereof.Type: ApplicationFiled: June 7, 2013Publication date: October 3, 2013Inventors: David Vandroux, Emmanuel De Maistre, Edouard Prost
-
Publication number: 20130252284Abstract: This invention provides a novel cellulase derived from Thermosporothrix hazakensis. The cellulase derived from Thermosporothrix hazakensis has enzyme activity on at least ?-glucan, soluble cellulose, crystalline cellulose, phosphoric acid-swollen cellulose, and xylan.Type: ApplicationFiled: May 31, 2012Publication date: September 26, 2013Applicant: Kennan Eisei Kogyo Co., Ltd.Inventors: Shuhei Yabe, Yoshifumi Aiba, Yasuteru Sakai, Akira Yokota
-
Publication number: 20130252830Abstract: The present disclosure is directed to a novel, unexpected approach of expressing exogenous gene(s) at increased levels by predictably, optionally irreversibly, incorporating the gene(s) into a region of increased gene expression (RIDGE) on a chromosome of a host cell. This approach is accomplished by identification of RIDGE(s) and further by integration of integrase-specific sites (e.g., attP or attB) in the presence of or mediated by integrase. The approach renders a high level of gene expression; predictability of the location of the exogenous genes, elimination of genetic instability or unwanted phenotype; and reduction of time and cost in optimizing protein production in host cells, which will be every useful in the production of therapeutic, prophylactic, and diagnostic proteins.Type: ApplicationFiled: November 25, 2011Publication date: September 26, 2013Applicant: APPLIED STEMCELL, INC.Inventors: James Zhu, Guoliang Yu